WallStSmart
RNAC

Cartesian Therapeutics Inc.

NASDAQ: RNAC · HEALTHCARE · BIOTECHNOLOGY

$6.22
-3.86% today

Updated 2026-04-30

Market cap
$199.26M
P/E ratio
P/S ratio
71.24x
EPS (TTM)
$-5.02
Dividend yield
52W range
$6 – $16
Volume
0.2M

Cartesian Therapeutics Inc. (RNAC) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201420152016201720182019202020212022202320242025
Revenue$3.04M$6.01M$8.08M$207000.00$903000.00$6.68M$16.60M$85.08M$110.78M$26.00M$38.91M$2.80M
Revenue growth (YoY)+97.7%+34.5%-97.4%+336.2%+639.4%+148.6%+412.6%+30.2%-76.5%+49.6%-92.8%
Cost of revenue$17.57M$14.59M$15.30M$45.16M$47.69M$42.74M$2.04M$1.55M
Gross profit$3.04M$6.01M$8.08M$207000.00$903000.00$6.68M$16.60M$85.08M$108.74M$26.00M$38.91M$2.80M
Gross margin100.0%100.0%100.0%100.0%100.0%100.0%100.0%100.0%98.2%100.0%100.0%100.0%
R&D$10.49M$22.98M$29.70M$45.16M$47.69M$42.74M$54.51M$68.74M$72.38M$71.26M$45.10M$58.03M
SG&A$7.95M$8.34M$13.05M$18.83M$18.24M$16.39M$18.91M$20.94M$23.86M$40.45M$30.13M$31.47M
Operating income$-15.40M$-25.30M$-34.67M$-63.78M$-65.02M$-52.45M$-56.82M$-4.60M$14.54M$-86.42M$-43.90M$-86.70M
Operating margin-506.5%-421.0%-428.9%-30813.5%-7200.7%-785.6%-342.4%-5.4%13.1%-332.3%-112.8%-3099.9%
EBITDA$-11.46M$-23.18M$-34.16M$-63.37M$-62.87M$-51.80M$-65.59M$-5.16M$39.84M$-235.03M$-75.99M$-86.70M
EBITDA margin-377.1%-385.7%-422.6%-30611.1%-6962.0%-775.9%-395.2%-6.1%36.0%-903.8%-195.3%-3099.9%
EBIT$-12.33M$-24.23M$-34.96M$-64.11M$-63.84M$-53.83M$-67.32M$-6.88M$37.80M$-235.88M$-77.14M
Interest expense$552000.00$948000.00$1.25M$1.21M$1.49M$1.52M$1.56M$2.84M$3.03M$2.83M$0.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-12.88M$-25.17M$-36.21M$-65.32M$-65.34M$-55.35M$-68.88M$-25.69M$35.38M$-219.71M$-77.42M$-130.30M
Net income growth (YoY)-95.5%-43.8%-80.4%-0.0%+15.3%-24.4%+62.7%+237.7%-721.0%+64.8%-68.3%
Profit margin-423.7%-418.8%-448.0%-31556.0%-7235.4%-829.0%-415.0%-30.2%31.9%-844.9%-199.0%-4658.6%